ABT ‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Arthritis&Rheumatology, EarlyView.

Source: Arthritis and Rheumatology - October 10, 2018 Category: Rheumatology Authors: Mark C. Genovese, Michael E. Weinblatt, Jacob A. Aelion, Heikki T. Mansikka, Paul M. Peloso, Kun Chen, Yihan Li, Ahmed A. Othman, Amit Khatri, Nasser S. Khan, Robert J. Padley Source Type: research